Amina Ahmed
Memorial Sloan Kettering Cancer Center
2 Papers
Amina Ahmed is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cytarabine & Etoposide. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Ayuko Hoshino,Ayuko Hoshino,Han Sang Kim,Han Sang Kim,Linda Bojmar,Linda Bojmar,Linda Bojmar,Kofi Ennu Gyan,Michele Cioffi,Jonathan M. Hernandez,Jonathan M. Hernandez,Jonathan M. Hernandez,Constantinos P. Zambirinis,Constantinos P. Zambirinis,Gonçalo Rodrigues,Gonçalo Rodrigues,Henrik Molina,Søren Heissel,Milica Tesic Mark,Loïc Steiner,Loïc Steiner,Alberto Benito-Martin,Serena Lucotti,Angela Di Giannatale,Katharine Offer,Miho Nakajima,Caitlin Williams,Laura Nogués,Laura Nogués,Fanny A. Pelissier Vatter,Ayako Hashimoto,Ayako Hashimoto,Ayako Hashimoto,Alexander E. Davies,Daniela Freitas,Daniela Freitas,Candia M. Kenific,Yonathan Ararso,Weston Buehring,Pernille Lauritzen,Yusuke Ogitani,Kei Sugiura,Kei Sugiura,Naoko Takahashi,Maša Alečković,Kayleen A. Bailey,Joshua S. Jolissant,Joshua S. Jolissant,Huajuan Wang,Ashton Harris,L. Miles Schaeffer,Guillermo García-Santos,Guillermo García-Santos,Zoe Posner,Vinod P. Balachandran,Yasmin Khakoo,G. Praveen Raju,Avigdor Scherz,Irit Sagi,Ruth Scherz-Shouval,Yosef Yarden,Moshe Oren,Mahathi Malladi,Mary Petriccione,Kevin C. De Braganca,Maria Donzelli,Cheryl Fischer,Stephanie Vitolano,Geraldine P. Wright,Lee Ganshaw,Mariel Marrano,Amina Ahmed,Joe DeStefano,Enrico Danzer,Michael H.A. Roehrl,Norman J. Lacayo,Theresa C. Vincent,Theresa C. Vincent,Martin R. Weiser,Mary S. Brady,Paul A. Meyers,Leonard H. Wexler,Srikanth R. Ambati,Alexander J. Chou,Emily K. Slotkin,Shakeel Modak,Stephen S. Roberts,Ellen M. Basu,Daniel Diolaiti,Benjamin A. Krantz,Benjamin A. Krantz,Fatima Cardoso,Amber L. Simpson,Michael F. Berger,Charles M. Rudin,Diane M. Simeone,Maneesh Jain,Cyrus M. Ghajar,Surinder K. Batra,Ben Z. Stanger,Jack D. Bui,Kristy A. Brown,Vinagolu K. Rajasekhar,John H. Healey,Maria de Sousa,Maria de Sousa,Kim Kramer,Sujit Sheth,Jeanine Baisch,Virginia Pascual,Todd E. Heaton,Michael P. La Quaglia,David J. Pisapia,Robert E. Schwartz,Haiying Zhang,Yuan Liu,Arti Shukla,Laurence Blavier,Yves A. DeClerck,Mark A. LaBarge,Mina J. Bissell,Thomas C. Caffrey,Paul M. Grandgenett,Michael A. Hollingsworth,Jacqueline Bromberg,Jacqueline Bromberg,Bruno Costa-Silva,Héctor Peinado,Yibin Kang,Benjamin A. Garcia,Eileen M. O'Reilly,David P. Kelsen,Tanya M. Trippett,David R. Jones,Irina Matei,William R. Jarnagin,David Lyden +136 more
TL;DR: EVP proteins can serve as reliable biomarkers for cancer detection and determining cancer type, and a panel of tumor-type-specific EVP proteins in TEs and plasma are defined, which can classify tumors of unknown primary origin.
936
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Todd Cooper,Edward Allan R. Sison,Sharyn D. Baker,Lie Li,Amina Ahmed,Tanya M. Trippett,Lia Gore,Margaret E. Macy,Aru Narendran,Keith J. August,Michael J. Absalon,Jessica Boklan,Jessica A. Pollard,Daniel Magoon,Patrick A. Brown +14 more
TL;DR: A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia, acute myeloid leukemia (AML), and myelodysplastic syndrome was performed to determine a tolerable and biologically active dose.